With a mission to fast-track therapeutics development and improve drug properties and performance, Intrepid Labs leverages a unique closed-loop technology to efficiently explore formulation design spaces, driving advancements in therapies and personalised medicine.
Spun out of the University of Toronto’s Acceleration Consortium, Intrepid Labs unites a multidisciplinary team dedicated to addressing bottlenecks in drug formulation. Backed by Propagator Ventures, Intrepid Labs is committed to delivering better medicine, faster, through cutting-edge automation and AI-driven solutions.
Co-investor in Intrepid Labs is Radical Ventures (CAN).
More on why we invested in Intrepid Labs here.